Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference

Rhea-AI Summary

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotech firm, will participate in the Bank of America 2022 Precision Oncology Conference on October 3, 2022, at 12:20 p.m. ET. The company's innovative Gene Traffic Control platform aims to address gene expression issues in serious diseases, with a primary focus on oncology. A webcast of the event will be available on their website for 90 days post-event. Foghorn is developing several oncology product candidates, with two currently in clinical trials.

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will participate in the Bank of America 2022 Precision Oncology Conference, which will be held virtually on October 3^rd, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Fireside chat date and time: Monday, October 3^rd, 2022, at 12:20 p.m. ET

Please find a link to the fireside chat here.

A webcast of the fireside chat and presentation will be accessible under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will remain available for up to 90 days.

About Foghorn Therapeutics
Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary and scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies. Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com

Michael Lampe, ScientPR (Media)
michael@scientpr.com

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com

FAQ

What is the date of Foghorn Therapeutics' participation in the Bank of America 2022 Precision Oncology Conference?

Foghorn Therapeutics will participate on October 3, 2022.

What time will Foghorn's fireside chat take place at the conference?

The fireside chat will take place at 12:20 p.m. ET.

How can I access Foghorn Therapeutics' webcast from the conference?

The webcast will be available under 'Events & Presentations' on Foghorn's website.

What is the focus of Foghorn's Gene Traffic Control platform?

The platform focuses on correcting abnormal gene expression in serious diseases, primarily in oncology.

How long will the webcast of Foghorn's presentation be available?

The webcast will remain available for up to 90 days.